Sansheng Pharmaceutical Co., Ltd. in the first half of 2018: revenue increased by 27%, market share of tebiao increased to more than 60%

[China Pharmaceutical network enterprise news] on August 20, Sansheng pharmaceutical released its performance in the first half of 2018 In the first half of this year, Sansheng pharmaceutical achieved operating revenue of about 2.174 billion yuan, an increase of 27.4% over the same period last year; gross profit of about 1.747 billion yuan, an increase of 19.9% over the same period last year; normalized EBITDA of about 838 million yuan, an increase of 25.7% over the same period last year; normalized net profit of about 561 million yuan, an increase of 37.8% over the same period last year According to the semi annual report of Sansheng pharmaceutical, in the first half of 2018, four core products, tebio, yisepu, yibio and saibor, continue to maintain the leading position in the Chinese market IMS data shows that in the first half of 2018, the market share of tebio for the treatment of thrombocytopenia increased to 63.2%; the market share of lisep for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis increased to 63.5%; the market share of lisbio and Saibo, two recombinant human erythropoietin products, was 41.3% In terms of product line, on May 25, this year, BSP and AstraZeneca cooperated to launch baidayan, which is a once-a-week hypoglycemic drug launch in China, bringing new treatment options for patients with type 2 diabetes In addition, in the field of Nephrology, Sansheng pharmaceutical added two new products this year: Pruritus product TRK-820 ("remitch"), which signed a license agreement with Toray Japan, and calcium acetate, a hyperphosphatemic product for the treatment of patients with chronic kidney disease, which was purchased from a pharmaceutical company BMT in Beijing At the same time, in the field of Dermatology, fluticasone propionate cream for the treatment of a variety of skin diseases was launched in March this year Laiz (pediatric indication) for the treatment of children's moderate to severe specific dermatitis was approved by the State Drug Administration In addition, in April 2018, Sansheng pharmaceutical and refuge biotechnology, Inc ("refuge") launched a cooperative research on the development of programmed cell therapy As of June 31, 2018, the company has 32 products under research, covering five fields including oncology, autoimmune diseases and other diseases, Nephrology, metabolism and dermatology, 17 of which are national first-class new drugs In terms of research and development, Sansheng pharmaceuticals said that the three phase of the trial of the etanercept prefilled syringe and clindamycin phosphate vitamin A acid gel (for local treatment of acne vulgaris); the second generation recombinant human erythropoietin product NuPIAO (SSS06) for anemia has completed many clinical trials, and has obtained the approval of the two and three phase clinical trials The anti epidermal growth factor receptor antibody 602 for tumor treatment completed the first phase of clinical trial, and planned to carry out the third phase of clinical trial in colorectal cancer patients; tebiao obtained the ind approval for the treatment of children's immune thrombocytopenia, and started the trial of liver dysfunction patients with thrombocytopenia risk; Anti VEGF antibody 601a was approved for three clinical trials of macular edema, myopic choroidal neovascularization (mcnv) and diabetic macular edema (DME) caused by retinal vein occlusion (RVO) Patients who started the first phase clinical trial of senile macular degeneration (AMD) were enrolled into the group; 302H, an anti HER2 monoclonal antibody drug for breast cancer treatment, has recently submitted a new drug marketing license application to the State Drug Administration For the future long-term development, Sansheng pharmaceutical said that the goal is to build a global pharmaceutical company based in China by using a platform integrating R & D, production and commercial promotion In the field of biological products, Sansheng pharmaceutical's product lines include nupiao, rd001, yisaipu's pre filled injection and other monoclonal antibody products; its monoclonal antibody production capacity reaches 38000 liters, and it has mammalian cell, bacterial and small molecule production facilities to create a profitable CMO business At the level of extension development, Sansheng pharmaceutical said it would continue to selectively seek opportunities for M & A and cooperation to enrich its existing product portfolio and products under research Lou Jing, chairman of Sansheng pharmaceutical, said that in the future, Sansheng pharmaceutical will continue to focus on the field of biopharmaceutical, providing innovative, affordable and global quality standard drugs to the public to meet the needs of more patients Original title: Sansheng pharmaceutical in the first half of 2018: revenue growth 27% market share of tebiao increased to over 60%